Genetic Engineering Drug Market SWOT Analysis 2021-2031
The Genetic Engineering Drug Market is expected to register a CAGR of 10.1% from 2024 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Genetic Engineering Drug Market report covers analysis By Product Type (Monoclonal Antibody, Recombinant Human Erythropoietin, Recombinant Human Interferon, Recombinant Human Growth Hormone, Recombinant Human Insulin); End users (Pharmaceutical Industries, Academic Institutes, Agriculture, Others). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Genetic Engineering Drug Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Genetic Engineering Drug Market Segmentation
Product Type- Monoclonal Antibody
- Recombinant Human Erythropoietin
- Recombinant Human Interferon
- Recombinant Human Growth Hormone
- Recombinant Human Insulin
- Pharmaceutical Industries
- Academic Institutes
- Agriculture
Strategic Insights
Genetic Engineering Drug Market Growth Drivers- Biotechnology Breakthroughs: Genetic engineering drug market is driven by the breakthrough in biotechnology that enables precision medicine. The market trend shows the increased use of genetic engineering to develop personalized treatments, which has increased the global market size.
- Increased prevalence of genetic disorders: Growing genetic and rare diseases boost the requirement for novel genetic therapies.
- Government Support: Government funding for research and healthcare infrastructure development encourages the growth of the market, according to market reports.
- Partnerships and collaborations: Strategic collaborations among biotech firms are accelerating genetic drug development. Market strategies emphasize partnerships for R&D and market expansion.
- Growing Adoption of Gene Therapies: Gene therapies, which involve altering the genetic material within a patient's cells to treat or prevent diseases, are gaining momentum in the market. These therapies are being developed to target diseases with genetic causes, such as sickle cell anemia and muscular dystrophy, and are expected to play a pivotal role in treating genetic disorders.
- Biologics and Biosimilars Growth: Biologics, drugs derived from living organisms and often involving genetic engineering, are gaining popularity due to their efficacy in treating complex diseases like cancer, autoimmune disorders, and genetic conditions. The growth of biosimilars, generic versions of biologics, is also contributing to market expansion as they offer cost-effective alternatives.
- Expansion in Rare and Underserved Diseases: There is a growing opportunity to develop genetic engineering drugs for rare and underserved genetic diseases that currently have limited treatment options. These diseases, such as rare inherited disorders and certain types of cancer, represent a largely untapped market for genetic-based therapies.
- Emerging Markets: The demand for advanced genetic treatments will grow as medical access expands in emerging markets. Potential areas of expansion include the Asia-Pacific region, Latin America, and the Middle East for companies engaged in genetic engineering drugs due to change in health systems and consciousness about the diseases.
- Regulatory Advances and Accelerated Pathways for Approval: The adoption of rapid regulatory pathways for gene therapy drugs such as accelerated approval and orphan drug designations has provided avenues for faster launches of genetic engineering drugs. These regulatory agencies are making quick work of streamlining the whole process for new treatments related to rare genetic disorders; thus, innovative therapies would be accessible quickly.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Genetic Engineering Drug Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Genetic Engineering Drug Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Some of the customization options available based on request are additional 3-5 company profiles and country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Key companies of this market are: Shanghai Lansheng Guojian Pharmaceutical, Biotech Pharmaceutical, GeneScience Pharmaceuticals, Beijing SL Pharmaceutical, Anhui Anke Biotechnology, 3SBio, Jiangsu Sihuan Bioengineering, Tonghua Dongbao Pharmaceutical, Shenzhen Neptunus Interlong Bio-Technique.
Key future trends in this market are - Progress in CRISPR Technology, Investment in Personalized Medicine, Collaboration and Licensing Deals
The Genetic Engineering Drug Market is estimated to witness a CAGR of 10.1% from 2023 to 2031.
The major factors driving the Market are: Biotechnology advancements, Increasing genetic disorder cases, Strategic collaborations and R&D
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Genetic Engineering Drug Market - By Product Type
1.3.2 Genetic Engineering Drug Market - By End users
1.3.3 Genetic Engineering Drug Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. GENETIC ENGINEERING DRUG MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. GENETIC ENGINEERING DRUG MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. GENETIC ENGINEERING DRUG MARKET - GLOBAL MARKET ANALYSIS
6.1. GENETIC ENGINEERING DRUG - GLOBAL MARKET OVERVIEW
6.2. GENETIC ENGINEERING DRUG - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. GENETIC ENGINEERING DRUG MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPE
7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. MONOCLONAL ANTIBODY
7.3.1. Overview
7.3.2. Monoclonal Antibody Market Forecast and Analysis
7.4. RECOMBINANT HUMAN ERYTHROPOIETIN
7.4.1. Overview
7.4.2. Recombinant Human Erythropoietin Market Forecast and Analysis
7.5. RECOMBINANT HUMAN INTERFERON
7.5.1. Overview
7.5.2. Recombinant Human Interferon Market Forecast and Analysis
7.6. RECOMBINANT HUMAN GROWTH HORMONE
7.6.1. Overview
7.6.2. Recombinant Human Growth Hormone Market Forecast and Analysis
7.7. RECOMBINANT HUMAN INSULIN
7.7.1. Overview
7.7.2. Recombinant Human Insulin Market Forecast and Analysis
8. GENETIC ENGINEERING DRUG MARKET - REVENUE AND FORECASTS TO 2028 - END USERS
8.1. OVERVIEW
8.2. END USERS MARKET FORECASTS AND ANALYSIS
8.3. PHARMACEUTICAL INDUSTRIES
8.3.1. Overview
8.3.2. Pharmaceutical Industries Market Forecast and Analysis
8.4. ACADEMIC INSTITUTES
8.4.1. Overview
8.4.2. Academic Institutes Market Forecast and Analysis
8.5. AGRICULTURE
8.5.1. Overview
8.5.2. Agriculture Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis
9. GENETIC ENGINEERING DRUG MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Genetic Engineering Drug Market Overview
9.1.2 North America Genetic Engineering Drug Market Forecasts and Analysis
9.1.3 North America Genetic Engineering Drug Market Forecasts and Analysis - By Product Type
9.1.4 North America Genetic Engineering Drug Market Forecasts and Analysis - By End users
9.1.5 North America Genetic Engineering Drug Market Forecasts and Analysis - By Countries
9.1.5.1 United States Genetic Engineering Drug Market
9.1.5.1.1 United States Genetic Engineering Drug Market by Product Type
9.1.5.1.2 United States Genetic Engineering Drug Market by End users
9.1.5.2 Canada Genetic Engineering Drug Market
9.1.5.2.1 Canada Genetic Engineering Drug Market by Product Type
9.1.5.2.2 Canada Genetic Engineering Drug Market by End users
9.1.5.3 Mexico Genetic Engineering Drug Market
9.1.5.3.1 Mexico Genetic Engineering Drug Market by Product Type
9.1.5.3.2 Mexico Genetic Engineering Drug Market by End users
9.2. EUROPE
9.2.1 Europe Genetic Engineering Drug Market Overview
9.2.2 Europe Genetic Engineering Drug Market Forecasts and Analysis
9.2.3 Europe Genetic Engineering Drug Market Forecasts and Analysis - By Product Type
9.2.4 Europe Genetic Engineering Drug Market Forecasts and Analysis - By End users
9.2.5 Europe Genetic Engineering Drug Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Genetic Engineering Drug Market
9.2.5.1.1 Germany Genetic Engineering Drug Market by Product Type
9.2.5.1.2 Germany Genetic Engineering Drug Market by End users
9.2.5.2 France Genetic Engineering Drug Market
9.2.5.2.1 France Genetic Engineering Drug Market by Product Type
9.2.5.2.2 France Genetic Engineering Drug Market by End users
9.2.5.3 Italy Genetic Engineering Drug Market
9.2.5.3.1 Italy Genetic Engineering Drug Market by Product Type
9.2.5.3.2 Italy Genetic Engineering Drug Market by End users
9.2.5.4 Spain Genetic Engineering Drug Market
9.2.5.4.1 Spain Genetic Engineering Drug Market by Product Type
9.2.5.4.2 Spain Genetic Engineering Drug Market by End users
9.2.5.5 United Kingdom Genetic Engineering Drug Market
9.2.5.5.1 United Kingdom Genetic Engineering Drug Market by Product Type
9.2.5.5.2 United Kingdom Genetic Engineering Drug Market by End users
9.2.5.6 Rest of Europe Genetic Engineering Drug Market
9.2.5.6.1 Rest of Europe Genetic Engineering Drug Market by Product Type
9.2.5.6.2 Rest of Europe Genetic Engineering Drug Market by End users
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Genetic Engineering Drug Market Overview
9.3.2 Asia-Pacific Genetic Engineering Drug Market Forecasts and Analysis
9.3.3 Asia-Pacific Genetic Engineering Drug Market Forecasts and Analysis - By Product Type
9.3.4 Asia-Pacific Genetic Engineering Drug Market Forecasts and Analysis - By End users
9.3.5 Asia-Pacific Genetic Engineering Drug Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Genetic Engineering Drug Market
9.3.5.1.1 Australia Genetic Engineering Drug Market by Product Type
9.3.5.1.2 Australia Genetic Engineering Drug Market by End users
9.3.5.2 China Genetic Engineering Drug Market
9.3.5.2.1 China Genetic Engineering Drug Market by Product Type
9.3.5.2.2 China Genetic Engineering Drug Market by End users
9.3.5.3 India Genetic Engineering Drug Market
9.3.5.3.1 India Genetic Engineering Drug Market by Product Type
9.3.5.3.2 India Genetic Engineering Drug Market by End users
9.3.5.4 Japan Genetic Engineering Drug Market
9.3.5.4.1 Japan Genetic Engineering Drug Market by Product Type
9.3.5.4.2 Japan Genetic Engineering Drug Market by End users
9.3.5.5 South Korea Genetic Engineering Drug Market
9.3.5.5.1 South Korea Genetic Engineering Drug Market by Product Type
9.3.5.5.2 South Korea Genetic Engineering Drug Market by End users
9.3.5.6 Rest of Asia-Pacific Genetic Engineering Drug Market
9.3.5.6.1 Rest of Asia-Pacific Genetic Engineering Drug Market by Product Type
9.3.5.6.2 Rest of Asia-Pacific Genetic Engineering Drug Market by End users
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Genetic Engineering Drug Market Overview
9.4.2 Middle East and Africa Genetic Engineering Drug Market Forecasts and Analysis
9.4.3 Middle East and Africa Genetic Engineering Drug Market Forecasts and Analysis - By Product Type
9.4.4 Middle East and Africa Genetic Engineering Drug Market Forecasts and Analysis - By End users
9.4.5 Middle East and Africa Genetic Engineering Drug Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Genetic Engineering Drug Market
9.4.5.1.1 South Africa Genetic Engineering Drug Market by Product Type
9.4.5.1.2 South Africa Genetic Engineering Drug Market by End users
9.4.5.2 Saudi Arabia Genetic Engineering Drug Market
9.4.5.2.1 Saudi Arabia Genetic Engineering Drug Market by Product Type
9.4.5.2.2 Saudi Arabia Genetic Engineering Drug Market by End users
9.4.5.3 U.A.E Genetic Engineering Drug Market
9.4.5.3.1 U.A.E Genetic Engineering Drug Market by Product Type
9.4.5.3.2 U.A.E Genetic Engineering Drug Market by End users
9.4.5.4 Rest of Middle East and Africa Genetic Engineering Drug Market
9.4.5.4.1 Rest of Middle East and Africa Genetic Engineering Drug Market by Product Type
9.4.5.4.2 Rest of Middle East and Africa Genetic Engineering Drug Market by End users
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Genetic Engineering Drug Market Overview
9.5.2 South and Central America Genetic Engineering Drug Market Forecasts and Analysis
9.5.3 South and Central America Genetic Engineering Drug Market Forecasts and Analysis - By Product Type
9.5.4 South and Central America Genetic Engineering Drug Market Forecasts and Analysis - By End users
9.5.5 South and Central America Genetic Engineering Drug Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Genetic Engineering Drug Market
9.5.5.1.1 Brazil Genetic Engineering Drug Market by Product Type
9.5.5.1.2 Brazil Genetic Engineering Drug Market by End users
9.5.5.2 Argentina Genetic Engineering Drug Market
9.5.5.2.1 Argentina Genetic Engineering Drug Market by Product Type
9.5.5.2.2 Argentina Genetic Engineering Drug Market by End users
9.5.5.3 Rest of South and Central America Genetic Engineering Drug Market
9.5.5.3.1 Rest of South and Central America Genetic Engineering Drug Market by Product Type
9.5.5.3.2 Rest of South and Central America Genetic Engineering Drug Market by End users
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL GENETIC ENGINEERING DRUG MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. GENETIC ENGINEERING DRUG MARKET, KEY COMPANY PROFILES
12.1. SHANGHAI LANSHENG GUOJIAN PHARMACEUTICAL
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BIOTECH PHARMACEUTICAL
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. GENESCIENCE PHARMACEUTICALS
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. BEIJING SL PHARMACEUTICAL
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ANHUI ANKE BIOTECHNOLOGY
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. 3SBIO
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. JIANGSU SIHUAN BIOENGINEERING
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. TONGHUA DONGBAO PHARMACEUTICAL
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. OTHERS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Shanghai Lansheng Guojian Pharmaceutical
2. Biotech Pharmaceutical
3. GeneScience Pharmaceuticals
4. Beijing SL Pharmaceutical
5. Anhui Anke Biotechnology
6. 3SBio
7. Jiangsu Sihuan Bioengineering
8. Tonghua Dongbao Pharmaceutical
9. Shenzhen Neptunus Interlong Bio-Technique
10. Others
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For